Sun Pharma Advanced Research Company (SPARC) has received a Complete Response Letter (CRL) from the United States Food & Drug Administration (USFDA) for the New Drug Application (NDA) for Taclantis (Paclitaxel Injection Concentrate for Suspension).
The company is reviewing the CRL and intends to work with the USFDA as soon as possible to address the concerns raised. As per the USFDA, a CRL is sent to an applicant if the agency determines that it will not approve the application or abbreviated application in its present form.
SPARC is an international pharmaceutical company engaged in research and development of drugs and delivery systems.
| Company Name | CMP |
|---|---|
| Syngene Internation. | 458.00 |
| Indegene | 529.65 |
| CMS Info Systems | 290.00 |
| JITF Infralogistics | 307.90 |
| Sagility | 44.18 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: